Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Arbutus Biopharma Corp
ABUSCurrent price
3.92 USD
+0.02 USD (+0.51%)
Last closed
3.87 USD
Company
www.arbutusbio.com
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
703 914 368 USD
Yield for 12 month
+82.33 %
1Y
3Y
5Y
10Y
15Y
ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Address: 701 Veterans Circle, Warminster, PA, United States, 18974
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
4.4 USDP/E ratio
–Dividend Yield
–Current Year
+18 141 000 USD
Last Year
+39 019 000 USD
Current Quarter
+1 532 000 USD
Last Quarter
+2 145 000 USD
Current Year
+16 737 000 USD
Last Year
+37 592 000 USD
Current Quarter
+1 177 000 USD
Last Quarter
+1 786 000 USD
Key Figures ABUS
1 year
3 years
5 years
10 years
EBITDA
-78 652 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-29.31 %
PEG Ratio
–
Return On Equity TTM
-57.54 %
Wall Street Target Price
4.4 USD
Revenue TTM
12 986 000 USD
Book Value
0.64 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-77.1 %
Dividend Yield
–
Gross Profit TTM
-45 389 000 USD
Earnings per share
-0.44 USD
Diluted Eps TTM
-0.44 USD
Most Recent Quarter
I 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ABUS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ABUS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:5
Payout Ratio
–
Last Split Date
04.11.2010
Dividend Date
–
Stock Valuation ABUS
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
22.0536
Price Sales TTM
28.9019
Enterprise Value EBITDA
-5.636
Price Book MRQ
4.9455
Financials ABUS
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ABUS
For 52 weeks
1.69 USD
3.89 USD
50 Day MA
3.23 USD
Shares Short Prior Month
5 370 956
200 Day MA
2.58 USD
Short Ratio
5.03
Shares Short
6 005 461
Short Percent
4.04 %
BeatStart